Our results, from human muscle and varying in vitro and in vivo experiments using pharmacological and genetic approaches, suggest that increased EGF-EGFR signaling contributes to ST fiber loss in COPD patients and demonstrate that EGFR signaling blockade promotes the development and maintenance of the ST muscle phenotype. Here, EGFR is linked to chronic obstructive pulmonary disease.